<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00691470</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-505</org_study_id>
    <nct_id>NCT00691470</nct_id>
  </id_info>
  <brief_title>Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation</brief_title>
  <acronym>EmbraceAC</acronym>
  <official_title>A Randomized, Double Blind Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARYx Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARYx Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test an experimental drug ATI-5923 vs Coumadin. The&#xD;
      study is intended to demonstrate ATI-5923 is superior to Coumadin for keeping INR values in&#xD;
      the desired therapeutic range. Patients who require chronic anticoagulation with one or more&#xD;
      of the following conditions are eligible for the study: atrial fibrillation or atrial&#xD;
      flutter, prosthetic heart valve, venous thromboembolic disease, or history of myocardial&#xD;
      infarction or cardiomyopathy will be enrolled.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary study objective is to evaluate whether ATI-5923 is superior to adjusted dose&#xD;
      warfarin in the quality of anticoagulation as measured by interpolated INR time in&#xD;
      therapeutic range. This is a Phase II/III multi-center, randomized, stratified, double blind,&#xD;
      parallel group, active control study comparing ATI-5923 with Coumadin in patients who require&#xD;
      chronic, oral anticoagulation. Up to 600 patients who successfully complete all screening&#xD;
      assessments and meet all eligibility criteria will be enrolled in the study and receive study&#xD;
      drug treatment for 6-12 months depending on time of study entry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">June 2009</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of time INR is in therapeutic range after the exclusion of the first 4 weeks of treatment, using the linear interpolation method of Rosendaal(Rosendaal, 1993).</measure>
    <time_frame>After the first month through end of study.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of all study recorded INR values that are within the target range, after the exclusion of the INR values from the first 4 weeks of treatment</measure>
    <time_frame>After the first month through end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of time patients have significant deviations from therapeutic INR range.</measure>
    <time_frame>After the first month through end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A composite of the following clinically important outcome events</measure>
    <time_frame>After the first month through end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <condition>Venous Thromboembolic Disease</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>1. ATI-5923</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose adjusted ATI-5923</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Coumadin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose adjusted Coumadin (warfarin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATI-5923</intervention_name>
    <description>Dose Adjusted based on INR.</description>
    <arm_group_label>1. ATI-5923</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coumadin (warfarin)</intervention_name>
    <description>Dose adjusted based on INR.</description>
    <arm_group_label>2. Coumadin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with one or more of the following indications for chronic warfarin&#xD;
             anticoagulation (the patient may either be a new candidate for anticoagulation or may&#xD;
             already be receiving warfarin):&#xD;
&#xD;
               1. Atrial fibrillation (paroxysmal, persistent or permanent, not due to a reversible&#xD;
                  cause, documented by ECG) or atrial flutter.&#xD;
&#xD;
               2. A prosthetic heart valve in the aortic or mitral position that requires chronic&#xD;
                  anticoagulation.&#xD;
&#xD;
               3. A history of venous thromboembolic disease (DVT and/or PE) requiring long term&#xD;
                  anticoagulation (&gt; 6 months).&#xD;
&#xD;
               4. A history of myocardial infarction or cardiomyopathy requiring anticoagulation.&#xD;
&#xD;
               5. Currently receiving chronic warfarin therapy for another indication not listed,&#xD;
                  with Sponsor approval.&#xD;
&#xD;
          2. Male or female greater than 18 years of age.&#xD;
&#xD;
          3. Able and willing to sign IRB approved written informed consent to participate in the&#xD;
             study.&#xD;
&#xD;
          4. Able and willing to follow instructions, to comply with protocol requirements, and to&#xD;
             attend required study visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications to anticoagulation as listed in the warfarin package insert&#xD;
             (Appendix D), such as active bleeding or lesions at risk of bleeding such as gastric&#xD;
             ulceration, colonic or cerebral AV malformations, cerebral or aortic aneurysms,&#xD;
             pericarditis or endocarditis. Patients who have had recent (&lt; 14 days from screening)&#xD;
             surgery or invasive procedures or are about to undergo surgery or other invasive&#xD;
             procedures, such as lumbar puncture. Patients with blood dyscrasias or inherited&#xD;
             disorders of hemostasis. Patients with a history of hemorrhagic tendencies or prior&#xD;
             serious hemorrhagic events such as hemorrhage within the cranium, eye, spinal cord,&#xD;
             retroperitoneum, or gastrointestinal tract.&#xD;
&#xD;
          2. Laboratory evidence at screening of clinically significant active bleeding, such as&#xD;
             unexplained positive occult blood in stool, or unexplained positive urinary blood that&#xD;
             is more than trace positive for hemoglobin.&#xD;
&#xD;
          3. Concomitant use of other anticoagulant or antiplatelet agents that may add to the&#xD;
             hemostatic burden such as clopidogrel, ticlopidine, heparin or low molecular weight&#xD;
             heparin (LMWH), or regular use of non selective long acting NSAIDs that cannot be&#xD;
             discontinued prior to initiating ATI 5923/warfarin dosing (daily use of 81-100 mg&#xD;
             aspirin is allowed).&#xD;
&#xD;
          4. A life expectancy of &lt; 1 year, end stage renal failure requiring dialysis, end stage&#xD;
             pulmonary disease requiring home oxygen, severe heart failure (NYHA class IV).&#xD;
&#xD;
          5. Dementia, severe psychiatric disorder, or ongoing alcohol or substance abuse.&#xD;
&#xD;
          6. Laboratory screening values indicating severe anemia (Hb &lt; 10 gm/L), thrombocytopenia&#xD;
             (platelet count &lt; 90,000/mcL), or active liver disease.&#xD;
&#xD;
          7. Patients with conditions that will interfere with determination of the INR using the&#xD;
             INRatio device, i.e., hematocrit &lt;30% or &gt;55%. Patients with the antiphospholipid&#xD;
             syndrome may have abnormal INR results and should not be enrolled.&#xD;
&#xD;
          8. History of non disabling ischemic stroke within the last 3 months, prior major&#xD;
             disabling ischemic stroke, or any history of intracranial bleeding.&#xD;
&#xD;
          9. Pregnant or nursing women or women of childbearing potential who will not use adequate&#xD;
             contraception, such as oral or implantable contraceptives, IUD, or barrier methods&#xD;
             (IUD or condom) with spermicide.&#xD;
&#xD;
         10. Currently participating in another clinical trial at screening, treatment with an&#xD;
             investigational drug within 30 days of the first dose of study medication, or patients&#xD;
             who previously participated in an ATI-5923 trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Birmingham Heart Clinic, PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>36693</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Center, PC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mobile Heart Specialists, PC</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36693</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Heart</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Escondido Cardiology Associates</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New West Physicians Clinical Research</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates of Fairfield County, PC</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stamford Therapeutics Consortium</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates of Fairfield County, PC</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Research Network, LLC</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Heart Center</name>
      <address>
        <city>Jacksonville Beach</city>
        <state>Florida</state>
        <zip>32250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Heart Center - Pavillon</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Heart Center - South</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cardiology Associates</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Heart Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart and Vascular Institute of Florida</name>
      <address>
        <city>Safety Harbor</city>
        <state>Florida</state>
        <zip>34695</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Heart Specialists</name>
      <address>
        <city>Covington</city>
        <state>Georgia</state>
        <zip>30014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Heart Center, PC</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Valley Clinical Research Center, LLC</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Heart and Lung Research Center</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DuPage Medical Group</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research Center</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart and Vascular Clinic</name>
      <address>
        <city>Lacombe</city>
        <state>Louisiana</state>
        <zip>70445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Androscoggin Cardiology Associates</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endeavor Medical Research, PLC</name>
      <address>
        <city>Alpena</city>
        <state>Michigan</state>
        <zip>49707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steljes Cardiology, PC</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Research Institute, LLC</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plaza Medical Group, PC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bend Memorial Clinic</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau Institute for Medical Research</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine of Greer</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Associates Clinic, LLP</name>
      <address>
        <city>Pierre</city>
        <state>South Dakota</state>
        <zip>57501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Research Institute of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Gottlieb, MD</name>
      <address>
        <city>Burien</city>
        <state>Washington</state>
        <zip>98166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.aryx.com/wt/page/ati5923</url>
    <description>EmbraceAC Study Site</description>
  </link>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>June 3, 2008</study_first_submitted>
  <study_first_submitted_qc>June 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2008</study_first_posted>
  <last_update_submitted>February 1, 2010</last_update_submitted>
  <last_update_submitted_qc>February 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Daniel Canafax</name_title>
    <organization>ARYx Therapeutics, Inc</organization>
  </responsible_party>
  <keyword>Anticoagulation</keyword>
  <keyword>Vitamin K-dependent clotting factor inhibitor</keyword>
  <keyword>Coumadin</keyword>
  <keyword>Warfarin</keyword>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Prosthetic heart valve</keyword>
  <keyword>Venous thromboembolic disease</keyword>
  <keyword>Myocardial infarction or cardiomyopathy</keyword>
  <keyword>Patients with one or more of the following indications for chronic warfarin anticoagulation:</keyword>
  <keyword>Atrial fibrillation (paroxysmal, persistent or permanent, not due to a reversible cause, documented by ECG) or atrial flutter;</keyword>
  <keyword>A prosthetic heart valve in the aortic or mitral position that requires chronic anticoagulation;</keyword>
  <keyword>A history of venous thromboembolic disease (DVT and/or PE) requiring long term anticoagulation (&gt; 6 months);</keyword>
  <keyword>A history of myocardial infarction or cardiomyopathy requiring anticoagulation.</keyword>
  <keyword>Currently receiving chronic warfarin therapy for another indication not listed, with Sponsor approval.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

